Cyclooxygenase inhibition and cardiovascular risk

[1] Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) : 490 - 496

[2] Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation [J]. FASEB JOURNAL, 2003, 17 (03) : 914 - +

[3] Belton O, 2000, CIRCULATION, V102, P840

[4] The Rresearch on Adverse Drug Events and Reports (RADAR) project [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2131 - 2140

[5] The use of nonsteroidal anti-inflammatory drugs (NSAIDs) - A science advisory from the American Heart Association [J]. CIRCULATION, 2005, 111 (13) : 1713 - 1716

[6] Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning [J]. CARDIOVASCULAR RESEARCH, 2002, 55 (03) : 506 - 519

[7] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528

[8] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102

[9] BROPHY J, 2005, HOT TOPIC CYCLOOXYGE

[10] Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension [J]. JOURNAL OF HYPERTENSION, 2003, 21 (09) : 1663 - 1667

[1] Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) : 490 - 496

[2] Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation [J]. FASEB JOURNAL, 2003, 17 (03) : 914 - +

[3] Belton O, 2000, CIRCULATION, V102, P840

[4] The Rresearch on Adverse Drug Events and Reports (RADAR) project [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2131 - 2140

[5] The use of nonsteroidal anti-inflammatory drugs (NSAIDs) - A science advisory from the American Heart Association [J]. CIRCULATION, 2005, 111 (13) : 1713 - 1716

[6] Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning [J]. CARDIOVASCULAR RESEARCH, 2002, 55 (03) : 506 - 519

[7] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528

[8] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102

[9] BROPHY J, 2005, HOT TOPIC CYCLOOXYGE

[10] Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension [J]. JOURNAL OF HYPERTENSION, 2003, 21 (09) : 1663 - 1667